A Trial of 2 Disease-Modifying Drugs (Metformin and N-acetylcysteine ) to Promote TB Lung Function Recovery

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

PHASE3

Total Enrollment

1104 participants

Study Classification

INTERVENTIONAL

Study Start Date

2026-01-31

Study Completion Date

2031-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Tuberculosis is a leading global cause of morbidity and mortality. Even if cured, a majority patients are left with bronchiectasis and fibrosis, permanent conditions that impair lung function. Large cohort studies have confirmed that even modest loss of lung function is associated with excess mortality risk. This study will examine if two treatments, metformin and N-acetylcysteine (NAC), can promote the recovery of lung function in TB if given together with standard TB treatment. There currently are no drugs approved for this indication.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Sputum Pharmacokinetics of TB Drugs and Bacterial Drug Resistance

NCT02534727

Tuberculosis Non-Tuberculosis Mycobacteria

COMPLETED

Tiotropium in Patients With Tuberculosis (TB) Destroyed Lung

NCT01365702

Lung Disease, Obstructive Tuberculosis

UNKNOWN

The Safety of Tuberculosis Treatments by Oral Inhalation

NCT01785927

Healthy

UNKNOWN PHASE1

Evaluate the Efficacy and Safety of FB2001 for Inhalation in Patients With Mild to Moderate COVID-19

NCT05675072

Mild to Moderate COVID-19

UNKNOWN PHASE2/PHASE3

Reducing Respiratory Symptoms of Pulmonary Irradiation in Interstitial Lung Disease

NCT05986318

Lung Cancer Interstitial Lung Disease

RECRUITING PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Tuberculosis is a leading global cause of morbidity and mortality. Current treatments are inadequate, requiring patients closely adhere to multi-drug regimens that are long, complex, and often poorly tolerated and/or ineffective. Even if cured, a majority patients are left with bronchiectasis and fibrosis, permanent conditions that impair lung function, particularly causing loss of FEV1% (the maximal 1-second exhaled volume in relation to age, sex, and height). FEV1 loss has profound long-term health consequences. Large cohort studies have confirmed that even modest loss of FEV1, remaining within 'normal' limits, is associated with excess mortality risk. This is most pronounced in low-income countries where TB is most prevalent. This study will examine if two treatments, metformin and N-acetylcysteine (NAC), can promote the recovery of lung function in TB. There currently are no drugs approved for this indication.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Tuberculosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Participants will be randomized 1:1:1 to the 3 arms.

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Metformin plus SOC

Metformin 1500 mg total daily for 6 months plus standard TB treatment

Group Type EXPERIMENTAL

Metformin

Intervention Type DRUG

Metformin 500 mg QAM x 1 wk, then 500 mg BID x 1 wk, then 1000 mg QAM and 500 mg QPM, plus standard TB treatment

N-acetylcysteine (NAC) plus SOC

NAC 3600 mg total daily for 6 months plus standard TB treatment

Group Type EXPERIMENTAL

N-Acetylcysteine (NAC) Treatment

Intervention Type DIETARY_SUPPLEMENT

N-acetylcysteine (NAC) 1800 mg orally twice daily plus standard TB treatment

Control (SOC)

Standard TB treatment alone

Group Type ACTIVE_COMPARATOR

Standard TB treatment

Intervention Type COMBINATION_PRODUCT

Standard TB treatment

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Metformin

Metformin 500 mg QAM x 1 wk, then 500 mg BID x 1 wk, then 1000 mg QAM and 500 mg QPM, plus standard TB treatment

Intervention Type DRUG

N-Acetylcysteine (NAC) Treatment

N-acetylcysteine (NAC) 1800 mg orally twice daily plus standard TB treatment

Intervention Type DIETARY_SUPPLEMENT

Standard TB treatment

Intervention Type COMBINATION_PRODUCT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Willing and able to provide signed written consent (or, in the case of illiteracy, witnessed oral consent plus patient thumbprint) prior to undertaking any trial-related procedures.
* Body weight (in light clothing without shoes) between 30 and 90 kg.
* Radiographic evidence of pulmonary tuberculosis
* Positive Xpert TB/RIF (original or Ultra) for MTB
* RIF susceptibility diagnosed by Xpert TB/RIF, with subsequent culture confirmation
* FEV1≤65% of predicted
* Eligible for treatment with a 6-month regimen comprised of INH, RIF, EMB, and PZA
* If sexually active, willing to use effective contraceptive methods for a period of 9 months (3 months post-study treatment)
* HIV-1 seronegative, or if HIV-1 seropositive, presenting to a non-India clinical site with a CD4 T cell count ≥100/µl and either receiving ART or willing to start ART during study participation
* SARS-CoV-2 PCR or antigen test negative, or if positive, either fully vaccinated against Covid-19 or with D-dimer \<1 µg/ml
* eGFR ≥30 ml/min/1.73 m2 (CKD EPI 2009)

Exclusion Criteria

* Any condition for which participation in the trial, as judged by the investigator, could compromise the well-being of the subject or prevent, limit or confound protocol specified assessments
* Currently pregnant or nursing, or pregnancy planned in next 12 months
* Is critically ill, and in the judgment of the investigator has a diagnosis likely to result in death during the trial or the follow-up period.
* TB meningitis or spondylitis, or other forms of severe tuberculosis with high risk of a poor outcome as judged by the investigator.
* History of allergy or hypersensitivity to any of the trial therapies or related substances.
* History of a chronic lung condition (including COPD or asthma) requiring treatment in the previous year
* Having participated in other clinical trials with investigational agents within 8 weeks prior to trial start or currently enrolled in an investigational trial.
* Prior TB treatment in the preceding 6 months, other than within the 7 days immediately prior to enrollment.
* Angina pectoris requiring treatment with nitroglycerin or other nitrates
* Cardiac arrhythmia requiring medication, or any clinically significant ECG abnormality, in the opinion of the investigator
* History of diabetes mellitus requiring treatment with metformin or resulting in hospitalization for hyper- or hypoglycaemia within the past year prior to start of screening
* Use of systemic corticosteroids within the past 28 days.
* Patients requiring treatment with medications not compatible with rifampin, such as HIV-1 protease inhibitors
* History of Pneumoconiosis.
* Subjects with any of the following abnormal laboratory values: hemoglobin \<8 g/dL, platelets \<100x109 cells/L, serum potassium \<3.5 mM/L, alanine aminotransferase (ALT) ≥2.0 x ULN, alkaline phosphatase (AP) \>5.0 x ULN, total bilirubin \>1.5 mg/dL, HbA1c \>6.5 %

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No